Updates From the Real-World Evidence Transparency Initiative

The ISPOR Real-World Evidence (RWE) Transparency Initiative moves forward towards the Society’s goals while underscoring the need for transparency in studies utilizing secondary data—especially for evaluating treatment effect or comparative-effectiveness research. This month, ISPOR and Pharmacoepidemiology & Drug Safety co-published recommendations from the Real-World Evidence Transparency Initiative in an article entitled ‘Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing—Why, What, and How: Recommendations and a Road Map From the Real-World Evidence Transparency Initiative.’ Read more here.